ACUT (Accustem Sciences) Land And Improvements : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Land And Improvements?

Accustem Sciences's land and improvements for the quarter that ended in Mar. 2025 was $0.00 Mil.

Accustem Sciences Land And Improvements Historical Data

The historical data trend for Accustem Sciences's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences Land And Improvements Chart

Accustem Sciences Annual Data

Trend

Dec22

Dec23

Dec24

Land And Improvements

Accustem Sciences Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Land And Improvements	Get a 7-Day Free Trial								-	-	-	-	-

Accustem Sciences Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Accustem Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Penn Plaza, Suite 1954, Floor 19th, New York, NY, USA, 10001

Website

https://www.accustem.com

Accustem Sciences Inc is a life sciences company that focuses on enhancing cancer patient outcomes through diagnostic, pharmaceutical, and medical device products. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services. Operations span New York, NY, and London, UK.